A metabolic engineering platform for macrolide combinatorial biosynthesis
Active Project Grant Awarded
- Award ID
- R16AI203187
- Recipient
-
Ferris State University UEI F7EQFJDU4495
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $132,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 5% complete
- Place of performance
- Big Rapids, MI 49307, USA
Award details come from USAspending.gov.
About this award
The National Institute of Allergy and Infectious Diseases awarded Ferris State University $132,000 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a metabolic engineering platform for macrolide combinatorial biosynthesis.
The funded research addresses antimicrobial resistance by designing and constructing novel biosynthetic pathways that produce new macrolide derivatives with altered hydroxylation and glycosylation patterns. The work leverages synthetic biology and macrolide-production superhosts to generate structural variants of 14-membered and 16-membered macrolides, then produces, isolates, and characterizes these new compounds. The research includes evaluation of the antimicrobial potential of newly synthesized metabolites against macrolide-resistant bacterial strains. Macrolides currently used clinically inhibit the 50S ribosomal subunit; resistance mechanisms include point mutations in 23S rRNA and methylation of critical residues that disrupt binding. The project hypothesizes that native glycosyltransferases will transfer deoxysugars to macrolide aglycones with sufficient substrate flexibility to generate effective structural variants.
Performance occurs at Big Rapids, Michigan. The project runs through August 31, 2030.
Description
- Abstract
- A metabolic engineering platform for macrolide combinatorial biosynthesis macrolides are natural product antibiotics clinically used to treat bacterial infections, but the emergence of macrolide resistance blunts the impact of current medications. Macrolides inhibit the 50S ribosomal subunit via hydrogen bonding to the 23S-rrna catalytic center, resulting in the termination of peptide translation. The deoxysugar moieties are required for binding to the 23S rrna. The primary resistance mechanisms for macrolides include point mutations in 23S rrna and methylation of critical residues that inhibit the intermolecular interactions between the deoxysugars and the 50S ribosomal subunit. Therefore, there is a vital need to develop new macrolide structural variants to overcome drug resistance. Structural modifications to the hydroxylation and glycosylation patterns are challenging via chemical synthetic and semi-synthetic techniques, so we propose to develop a biosynthetic system for reprogramming the pikromycin and spiramycin pathways. In this NIH sure R16 project, we will leverage synthetic biology to create a combinatorial biosynthesis platform for developing new 14-membered macrolides (14-MM) and 16-membered macrolides (16-MM). To facilitate the production of analogs, we will exploit macrolide-production superhosts for glycodiversification and CYP450 oxygenase overexpression experiments. The overall objectives of the proposed research are three- fold: (1) to design and construct novel biosynthetic pathways for macrolide production, (2) to produce, isolate, and structurally characterize new macrolide derivatives, (3) to evaluate the antimicrobial potential of these new metabolites. We hypothesize that (1) the native glycosyltransferases will be "substrate flexible" to transfer the intended TDP-deoxysugar donors to the macrolide aglycones, resulting in structural variants with optimized saccharide patterns; (2) the heterologously expressed CYP450S will introduce regiospecific hydroxylations and epoxidations, generating analogs with increased potency. Our specific aims will test these hypotheses: (aim 1) we will heterologously express "sugar plasmids" in the pikromycin and spiramycin-producing hosts to produce novel glycosylated macrolides, and (aim 2) we will express diverse CYP450 enzymes in these organisms to introduce new hydroxyl/epoxide functionalities into the macrolactone skeleton. New analogs will be rigorously characterized via NMR spectroscopy. The antimicrobial activity will be assessed via microbroth dilution antimicrobial susceptibility assay. Ribosome binding of the new analogs will be tested in an E. Coli S30 lysate assay. This contribution is significant because the expected production platform will more fully explore the chemical space of 14-MM and 16-MM. Furthermore, this research is innovative because IT is anticipated to result in a valuable synthetic biology platform for elaborating new macrolide drug leads.
Quick answers
Who received award R16AI203187?
R16AI203187 was awarded to Ferris State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 2, 2026.
How much is award R16AI203187 worth?
$132,000 has been obligated on R16AI203187.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award